MSFT   207.28 (+1.26%)
FB   235.29 (-0.95%)
GOOGL   1,469.40 (+1.90%)
AMZN   2,898.91 (+0.70%)
NVDA   385.84 (+1.22%)
MU   50.25 (+1.11%)
GE   6.88 (+1.93%)
TSLA   1,206.81 (+7.79%)
AMD   52.37 (-0.40%)
T   30.22 (+1.04%)
F   6.10 (+2.01%)
GILD   76.90 (+1.10%)
DIS   113.33 (+0.27%)
NFLX   479.34 (-1.30%)
BA   182.74 (+1.34%)
MSFT   207.28 (+1.26%)
FB   235.29 (-0.95%)
GOOGL   1,469.40 (+1.90%)
AMZN   2,898.91 (+0.70%)
NVDA   385.84 (+1.22%)
MU   50.25 (+1.11%)
GE   6.88 (+1.93%)
TSLA   1,206.81 (+7.79%)
AMD   52.37 (-0.40%)
T   30.22 (+1.04%)
F   6.10 (+2.01%)
GILD   76.90 (+1.10%)
DIS   113.33 (+0.27%)
NFLX   479.34 (-1.30%)
BA   182.74 (+1.34%)
MSFT   207.28 (+1.26%)
FB   235.29 (-0.95%)
GOOGL   1,469.40 (+1.90%)
AMZN   2,898.91 (+0.70%)
NVDA   385.84 (+1.22%)
MU   50.25 (+1.11%)
GE   6.88 (+1.93%)
TSLA   1,206.81 (+7.79%)
AMD   52.37 (-0.40%)
T   30.22 (+1.04%)
F   6.10 (+2.01%)
GILD   76.90 (+1.10%)
DIS   113.33 (+0.27%)
NFLX   479.34 (-1.30%)
BA   182.74 (+1.34%)
MSFT   207.28 (+1.26%)
FB   235.29 (-0.95%)
GOOGL   1,469.40 (+1.90%)
AMZN   2,898.91 (+0.70%)
NVDA   385.84 (+1.22%)
MU   50.25 (+1.11%)
GE   6.88 (+1.93%)
TSLA   1,206.81 (+7.79%)
AMD   52.37 (-0.40%)
T   30.22 (+1.04%)
F   6.10 (+2.01%)
GILD   76.90 (+1.10%)
DIS   113.33 (+0.27%)
NFLX   479.34 (-1.30%)
BA   182.74 (+1.34%)
Log in

NASDAQ:APVOAptevo Therapeutics Stock Price, Forecast & News

$9.39
+0.26 (+2.85 %)
(As of 07/2/2020 11:45 AM ET)
Add
Compare
Today's Range
$8.82
Now: $9.39
$9.39
50-Day Range
$5.07
MA: $6.21
$9.27
52-Week Range
$2.94
Now: $9.39
$14.28
Volume62,037 shs
Average Volume1.71 million shs
Market Capitalization$30.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More
Aptevo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APVO
CUSIPN/A
Phone206-838-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.42 million
Book Value$3.66 per share

Profitability

Net Income$-40,450,000.00
Net Margins-102.54%

Miscellaneous

Employees118
Market Cap$30.33 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

How has Aptevo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APVO shares have increased by 2,135.7% and is now trading at $9.39. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptevo Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptevo Therapeutics.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc (NASDAQ:APVO) issued its earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.84) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.35) by $0.49. Aptevo Therapeutics had a negative return on equity of 224.05% and a negative net margin of 102.54%. View Aptevo Therapeutics' earnings history.

What price target have analysts set for APVO?

1 analysts have issued 1 year price targets for Aptevo Therapeutics' shares. Their forecasts range from $3.00 to $18.50. On average, they anticipate Aptevo Therapeutics' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View analysts' price targets for Aptevo Therapeutics.

Has Aptevo Therapeutics been receiving favorable news coverage?

Media stories about APVO stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Aptevo Therapeutics.

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Amarin (AMRN), Axsome Therapeutics (AXSM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and Netflix (NFLX).

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 57)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
  • Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
  • Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $9.39.

How big of a company is Aptevo Therapeutics?

Aptevo Therapeutics has a market capitalization of $30.33 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.